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Abstract
Background: Adding testosterone to hormonal therapy could improve sexual function and general well-being
among women during climacteric. We evaluated the effectiveness of testosterone undecanoate on sexual function
in postmenopausal women utilizing the standardized questionnaire FSFI score.
Methods: Postmenopausal women with sexual complaints and Female Sexual Function Index (FSFI) ≤ 26.5 were
enrolled in to this randomized, double-blinded, placebo-controlled trial. Participants were randomly assigned to
8-week treatment with either oral testosterone undecanoate 40 mg or placebo twice weekly with daily oral
estrogen. The FSFI scores before and after treatment were compared to assess any improvement of sexual function.
Results: Seventy women were recruited of which each group had 35 participants. The baseline characteristics and
baseline FSFI scores were comparable between both groups. After 8 weeks of treatment, the FSFI scores
significantly improved in both groups when compared to the baseline but the FSFI scores from the testosterone
group were significantly higher than in the placebo group post-treatment (28.6 ± 3.6, 25.3 ± 6.7, respectively,
p = 0.04). There was no difference in adverse effect between the two groups
Conclusions: The twice weekly addition of testosterone undecanoate to daily oral estrogen was associated with a
significant improvement in sexual function among postmenopausal women than the use of the estrogen alone.
Trial registration: ClinicalTrials.gov Identifier NCT01724658 (February 17, 2012).
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Background
Among sexually active menopausal women, sexual dys-
function can significantly affect their quality of life. A
previous Thai study reported that up to 82 % of sexually
active, postmenopausal women had sexual dysfunction.
This was based on the overall Female Sexual Function
Index (FSFI) score of ≤ 26.5 among women who had a
positive attitude towards sex [1].
Several studies found that adding testosterone to hor-
monal therapy could improve sexual function and gen-
eral well-being among women during climacteric [2–12].
Significant improvement was seen by some variables
studies when surgical menopausal women were adminis-
tered 40 mg oral testosterone undecanoate daily together
with their estrogen therapy comparable to estrogen
alone [13].
For several decades, testosterone undecanoate has
been used for the treatment of male hypogonadism.
Based on a theoretical assumption that only 6 % of a
testosterone dose in male (testosterone undecanoate
120 mg/day) is sufficient for testosterone supplement for
females which would correspond to approximately
50 mg per week [14]. However, testosterone undecano-
ate 50 mg was not available in Thailand when we did
the pilot study so we used a single dose of 40 mg capsule
and assessed the level of total testosterone and free
androgen index after 72 h. The serum levels of total and
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free testosterone were higher than the baseline levels
(total testosterone: treatment VS baseline, 0.7 nmol/l VS
0.5 nmol/l; free androgen index; treatment VS baseline,
1.24 % VS 0.77 %). Based on these preliminary results,
we decided to use testosterone undecanoate 40 mg twice
weekly to ensure an adequate blood level and minimize
androgenic side effects.
The FSFI is a standardized questionnaire used to as-
sess sexual function among postmenopausal women.
This questionnaire has been validated in women with
clinical female sexual arousal disorder, hypoactive sexual
desire disorder, female orgasmic disorder, dyspareunia /
vaginismus, multiple sexual dysfunctions and is anonym-
ous patient-based self-reported instrument [15–18]. The
FSFI has been used worldwide to evaluate the treatment
outcome in clinical trials. We used the Thai version
which translation has been validated with high reliability
coefficients and internal consistency (r = 0.79-0.86,
Cronbach’s alpha value = 0.82, FSFI was translated in
Thai version and experts agree on validity, The FSFI was
tested reliability among Thai postmenopausal women).
We then evaluated the effectiveness of testosterone unde-
canoate on sexual function in postmenopausal women
utilizing the standardized questionnaire FSFI score.
Methods
This randomized, double-blind, controlled trial was per-
formed at the menopause clinic, King Chulalongkorn
Memorial Hospital. This study was approved by the
Institutional Review Board of the Faculty of Medicine,
Chulalongkorn University (102/55), and is registered in
the clinicaltrials.gov registry (ClinicalTrials.gov Identifier
NCT 01724658). This study followed CONSORT guide-
lines 2010 (Fig. 1).
All sexually active postmenopausal women who visited
the menopause clinic between June 2012 and February
2013 were invited to participate in this study. Women
between ages 40–60 years were eligible if they were in
natural or surgical menopause (history of 12 months of
amenorrhea or bilateral removal of both ovaries), sexu-
ally active, diagnosed with sexual dysfunction by having
FSFI scores ≤ 26.5 and literate. Postmenopausal women
with severe vasomotor symptoms, history of venous
thrombo-embolism, cerebrovascular disease or cardio-
vascular disease, cancer or liver disease, history of psy-
chiatric disorders, have used hormonal treatment or any
psychiatric drugs in the past 3 months, have abnormal
liver function test, abnormal lipid profiles (Triglyceride ≥
150 mg/dl, LDL ≥ 190 mg/dl) or partner with sexual
dysfunction were excluded from the study.
All subjects provided written informed consent before
any screening procedures were performed. The sample
size was estimated based on the results obtained from
our pilot study (the mean difference of FSFI was 4.8). A
total of 35 participants per group were needed when the
level of statistical significance was set at 0.05 % (α-error =
0.05) to yield a power of 80 % (β-error = 0.2). A 10 % esti-
mation of lost to follow-up was also incorporated into the
calculation.
Each participant was interviewed in order to obtain in-
formation related to sexual behaviors as well as basic pa-
tient information such as age, age at which menopause
occurred, type of menopause, marital status, weight,
height, BMI, frequency and severity of vasomotor symp-
toms and sexual history. After being informed about the
objective, methodology, and possible side effects of treat-
ment, the participants were randomized into 2 groups
by blocks of four, into either 8- week treatment with ei-
ther 40 mg of oral testosterone undecanoate or identical
placebo twice weekly (on Tuesday and Friday with
dinner meal) with daily estrogen (1 mg of estrogen valer-
ate). One pharmacist dispensed the testosterone unde-
canoate or placebo according to the blocks of four
randomization list. The testosterone undecanoate or pla-
cebo were packed in the dark and sealed envelopes and
consecutively numbered for each woman according to
the randomization schedule. Each participant was
assigned a number which corresponded with the admin-
istered drugs in the packed envelops. All participants,
care providers, research assistants and biostatisticians
were blinded to the study drug. Basic characteristics of
the participants were obtained through an interview at
baseline. The blood count, liver enzymes, lipid profile
and testosterone level were also assessed at baseline visit.
Total testosterone and SHBG were measured by the en-
zyme linked immunosorbent assay technique, inter-assay
and intra-assay coefficient of variations (CVs) of total
testosterone = 3.74 % and 2.24 %; inter-assay and intra-
assay CVs of SHBG = 3.46 % and 2.80 %, respectively).
The correct consumption procedures for testosterone
undecanoate, estrogen and placebo were given to all par-
ticipants. Each participant maintained a diary to record
any adverse effects of drugs. For any serious conditions,
the participants were instructed to call 24 h hotline. All
participants were interviewed by phone after 2 weeks of
drug consumption to assess the treatment compliance
and adverse effects. Participants were advised to come
back if they had any adverse effects and were
reminded to record their medication intake. Evalu-
ation after treatment was done at week 8 by using the
FSFI questionnaire. The blood samples were collected
to assess blood counts, liver enzymes, lipid profile and
testosterone level. Participants were interviewed and
recorded of any adverse effects such as acne, vaginal
bleeding and hirsutism. A 10 mg of medroxyprogester-
one acetate (MPA) was given to participants with in-
tact uterus at the end of the study for a total of
14 days.
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The primary efficacy variable was the improvement in
the FSFI score. The secondary outcomes were the
adverse effects of the drug (testosterone undecanoate)
such as acne, hirsutism and vaginal bleeding. Statistical
analysis was performed by using SPSS 17.0 Software. De-
scriptive statistics [mean (SD) or median (range) and
percentage] were used to present the demographic and,
baseline data, and measurement outcomes. ANCOVA
was used to compare the FSFI scores after treatment be-
tween the groups when the data was normally distrib-
uted. Mann–Whitney U test was used when the data
was not normally distributed. Chi-square test and
Fig. 1 Flow diagram of study, based on CONSORT guidelines 2010
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Fisher’s exact test were used to analyze the side effects
between both groups. A p-value of < 0.05 was considered
statistically significant. An intention-to-treat analysis was
used for all outcomes.
Results
A total of 76 postmenopausal women, who complained
of sexual problems, were screened for eligibility. Of
these women, 70 were included and randomly assigned
to the testosterone (twice weekly 40 mg of oral testoster-
one undecanoate plus daily 1 mg of oral estradiol valer-
ate) or the placebo group (placebo plus estrogen). Six
women were excludes because five women had anti-
psychotic drug and one woman had a partner that suf-
fering for erectile dysfunction. Only one woman in the
testosterone group was lost to follow up when she relo-
cated to another country. Baseline characteristics
between both groups were comparable for age, BMI,
duration of menopause, menopausal status and total
FSFI score (Table 1).
After 8 weeks of treatment, both groups showed sig-
nificant improvement in total FSFI score compared to
baseline. The total FSFI score (Table 2) and arousal
score (Table 3) from the testosterone group were signifi-
cantly higher than the placebo group (p < 0.05).
There was no serious adverse effect in this study. The
participants reported having mild acne and mild facial hair
growth which were comparable between both groups.
No vaginal bleeding was reported in both groups
(Table 4). There was no change in hematocrit, liver en-
zymes or lipid profile during the study period (Table 5).
The free androgen index in testosterone group was sig-
nificant higher than placebo group. (Table 6)
Discussion
We found that the 8 weeks of testosterone undecanoate
40 mg given twice weekly with daily estrogen was
associated with a significant improvement in the
women’s overall sexual function when compared with
estrogen alone, especially for the arousal domain. The
recorded adverse effects of low dose testosterone unde-
canoate administered for 8 weeks was comparable to the
placebo group for acne and hirsutism. We did not ob-
serve any vaginal bleeding. There were no changes in
hematocrit, liver enzymes or lipid profile after 8-weeks
of treatment. However, it is possible that the sample size
used in this study may not have been powered enough
to detect differences between the two groups with re-
spect to the safety variables.
Among couples, sexual intercourse is one of the most
important factors that can significantly affect the status
and health of the relationship. Female sexual dysfunction
is the result of interplay of biological, psychological,
physiological, status/health of the relationship and socio-
cultural factors. However, in postmenopausal women,
hormonal factor is deemed to be an important factor in-
fluencing female sexual dysfunction. Estrogen has been
shown to be associated with the woman’s sexual drive/
desire and used widely to relieve menopausal symptoms,
vaginal dryness, dyspareunia and to improve libido. On
the contrary, the role of testosterone in postmenopausal
hormone therapy is less clear. It is not as commonly pre-
scribed as estrogen which may partly be due to the con-
cern over side effect and long-term safety.
Previous studies have shown that low levels of testos-
terone were significantly associated with reduced sexual
desire, arousal and responsiveness in women [2, 3].
Other studies showed that by adding testosterone to
Table 1 Participants’ characteristics
Testosterone N = 35 Placebo N = 35 p value
Age (years) 53.8 ± 3.6 52.7 ± 4.1 0.23
Body Mass Index (kg/m2) 23.4 ± 2.9 23.7 ± 3.2 0.67
Years since menopause 6.2 ± 4.4 5.0 ± 3.4 0.60
Data are presented as mean ± SD, FSFI female sexual function index






Pre-treatment FSFI score 18.5 ± 5.8 16.3 ± 7.0 0.17
Post-treatment FSFI score 28.6 ± 3.6 25.3 ± 6.7 0.04
Data are presented as mean ± SD; FSFI = Female Sexual Function Index
aANCOVA was used to compare the FSFI scores between groups for
post-treatment FSFI




Testosterone N = 35 Placebo N = 35 p valueb
Baseline At 8 weeks Baseline At 8 weeks
Desire 2.42 3.47 2.35 3.15 0.99
Arousal 2.73 4.17 2.27 3.45 0.02
Lubrication 3.27 5.08 2.80 4.64 0.28
Orgasm 3.30 4.55 2.75 4.34 0.85
Satisfaction 3.82 5.17 3.35 4.82 0.17
Pain 3.03 5.36 2.85 4.88 0.16
Data are presented as mean
bANCOVA was used to compare the FSFI scores between
post-treatment groups
Table 4 Adverse effects
Symptoms Testosterone N = 35 Placebo N = 35 p value
Acne N (%) 6 (17.6) 5 (14.2) 0.10
Hirsutism N (%) 3 (8.8) 3 (8.5) 0.70
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hormonal therapy it can improve sexual function in
postmenopausal women [2–10]. These data indicate that
supplemental testosterone may help increase sexual
function in postmenopausal women but its short- and
long-term safety remains to be of concern [19]. Our
study was aimed to look into the short-term effects of
adding testosterone undecanoate to estrogen for the im-
provement of female sexual dysfunction among post-
menopausal women as well as its possible androgenic
side effects when administered a low dose of 40 mg
twice weekly.
Sexual function is difficult to assess because it is com-
posed of a combination of biological and psychological
factors/variables. Protocols to assess quality of sexual life
varied from study to study and make it difficult to com-
pare outcomes. In the present study, we used the FSFI
questionnaire which has been validated for various
aspects of sexual function and performance in pre and
postmenopausal women on estrogen and testosterone.
FSFI is a well-standardized questionnaire which objectively
assesses the subjective outcome. We used the FSFI total
score of 26.5 to be the optimal cutoff score because it has
been demonstrated to differentiate women with and with-
out sexual dysfunction [18].
Conclusions
This study appears to support the addition of the lower
dose and twice weekly administration of testosterone
undecanoate to daily estrogen for postmenopausal women
with female sexual dysfunction, however, a larger study
with a longer duration is needed to confirm the long-term
efficacy and safety profiles. Besides the monitoring of vagi-
nal bleeding, endometrial assessment should be properly
evaluated to confirm the testosterone effect on endomet-
rial safety. Partner’s influence should also be taken into ac-
count because it is known to have high influence over
female’s sexuality.
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